Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
B-HIVE
NCT02524106Phase 3Terminated
- Sponsor
- University of California, San Francisco
- Start
- Aug 2016
- Primary completion
- Nov 2017
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of bococizumab in dyslipidemia, cardiovascular disease (CVD), sponsored by University of California, San Francisco. Started Aug 2016; status: terminated.
02
Drugs
bococizumab
03
Conditions
dyslipidemiacardiovascular disease (CVD)
Beyond the preview
Go deeper on NCT02524106.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02524106.